E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
None; this proof-of-principle study will examine the cognition enhancing effects of roflumilast in healthy subjects |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Psychological processes [F02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate whether roflumilast improves declarative episodic memory. Memory function will be assessed using the verbal learning task (VLT), which assesses short- and long-term memory, using word lists. This task is particularly relevant since it assesses declarative episodic memory, a function primarily involving the hippocampus. Considering the evidence of high PDE-4 expression in this specific structure, we expect a larger effect size for cognitive functions related to this brain area. |
|
E.2.2 | Secondary objectives of the trial |
Our second objective is twofold. Other types of cognition will be measured using the Stroop task, continuous performance task (CPT) and the spatial memory task (SMT). The first two tasks measure response inhibition and focused attention, the latter task measures spatial memory. In addition, EEG recordings are included to gain insight in the electrophysiological correlates of cognition. A sensory gating paradigm is included which enables us to examine the effect of our treatment on specific ERP components related to basic auditory processing |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• 18 to 35 years of age
• Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity (corrected or uncorrected),
• Body mass index between 18.5 and 30
• Willingness to sign an informed consent.
• Positive evaluation on the memory screening
|
|
E.4 | Principal exclusion criteria |
Volunteers who suffer from, or have a history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric illness, will be excluded. Those volunteers who have a first-degree relative with a psychiatric disorder or a history of depressive disorder with or without suicidal risk will be excluded as well. Other exclusion criteria are excessive drinking (>20 glasses of alcohol containing beverages a week), pregnancy or lactation, use of chronic medication other than oral contraceptives, use of recreational drugs from 2 weeks before until the end of the experiment, smoking, orthostatic hypotension, lactose intolerance, and any sensory or motor deficits which could reasonably be expected to affect test performance. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Main study parameters are the scores on the memory tasks. The verbal learning task the object relocation task, and the spatial memory task are selected for this purpose. Secondary, the continuous performance test and the stroop task will be included to assess attention and response inhibition. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Data will be analysed after all 20 subjects have been tested. |
|
E.5.2 | Secondary end point(s) |
Event-related potentials inferred from the EEG signal during those tasks will be analysed. In addition, auditory evoked potentials will give an indication of the role of roflumilast in information processing. Finally, the ratio (S2/S1) of the P50 will be included as a measure of sensory gating. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Data will be analysed after all 20 subjects have been tested. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |